Please login to the form below
Takeda highlights 12 NMEs with $10bn-plus sales potential at R&D day
First wave of new molecular entities has potential to generate 14 approvals
Merck acquires pre-clinical biotech Calporta for up to $576m
Expands into early-stage neurodegeneration research field
Nucala works in rare inflammatory disease, says GSK
Company is planning to file for approval in indication next year
UK biotech Evgen craters on failed stroke trial
Shares in the biotech more than halved following the news
Otsuka presses on with Alzheimer’s agitation drug
Surprise announcement comes on the heels of phase 3 trial fail
Roche’s Spinraza, Zolgensma rival risdiplam hits the mark in SMA
Will file for approval in US and other world markets before end of the year
Novartis makes case for NASH candidate tropifexor
Race to market intensifies as rivals strive to win first-in-class
Takeda’s dengue vaccine seems safe with no prior virus exposure
Appears unaffected by serious safety issue affecting Sanofi rival
Evotec and Vifor announce joint venture for kidney disease treatments
Both companies will split the clinical and commercial costs equally
Adopting a creative IP approach towards biotech clusters
Why big pharma paradigm needs to change
-
A unique ecosystem How life science and healthcare clusters are driving innovation
-
Riding the wave of digital disruptionThe challenges and rewards of meeting consumer expectations
-
Trial backs Inovio/Sanofi combo in hard-to-treat brain cancerResults at six months demonstrated 75% of patients were progression-free
-
Aveo’s tivozanib is knocked back by FDA once againCompany says it will delay any regulatory filing until first quarter next year
-
Halozyme faces late-stage pancreatic cancer drug failure, cuts 55% of jobsWill now focus on its novel drug delivery platform to drive business growth
-
Sanofi reveals positive phase 3 results for long-acting insulin ToujeoHopes new product can offset continuing decline in franchise
-
China okays Green Valley’s algae-based drug for Alzheimer’s drug Due to start phase 3 trials in the US and Europe next year
-
Novartis’ Cosentyx misses the mark in Humira head-to-headNarrowly missed statistical significance for superiority
-
Amgen exits neuroscience R&D to focus on growth areasMove has resulted in loss of around 180 jobs
-
F-star hires ex-BMS immuno-oncology leader
New CMO to oversee development of lead candidate
-
Lilly appoints Maura Dickler as VP of late phase oncology developmentShe will join the pharma firm from the Memorial Sloan Kettering Cancer Center
-
Metrion Biosciences establishes scientific advisory board
The board will provide scientific oversight and strategic advice to Metrion
-
Dr Sotirios Stergiopoulos leaves Shire for IpsenHe becomes the French biopharma’s chief medical officer
-
Linda Law joins Advicenne as US VP, clinical development and med affairsShe will oversee the biopharma’s developments with its dTRA candidate
Latest research appointments
Featured jobs
- Entry Level Editorial Assistant – Medical Education –Buckinghams...
-
Highly Competitive
-
Senior Medical Writer
-
Salary TBC
- Scientific Director - Medical Communications - Berkshire
-
Excellent package on offer
-
Account Director, Medical Education
-
Salary TBC
- Senior Editor - Medical Communications - South East - Buckingham...
-
Highly competitive salary &package
-
Account Executive
-
Salary TBC
-
Account Supervisor
-
Salary TBC
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
-
Account Director
-
Salary TBC
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
Subscribe to our email news alerts
- Genital herpes vaccine candidate heads for human studies
- Roche’s Spinraza, Zolgensma rival risdiplam hits the mark in SMA
- FDA advisors say no to empagliflozin in type 1 diabetes
- Novartis makes case for NASH candidate tropifexor
- MSD hangs ‘for sale’ sign on French facility, shedding 207 staff
- AbbVie sells $30bn of bonds ahead of Allergan merger
- What do Healthcare Professionals think about the inclusion of remote selling techniques?
- Takeda highlights 12 NMEs with $10bn-plus sales potential at R&D day
- BeiGene bags FDA approval for first product Brukinsa in lymphoma
- Amarin wins FDA advisory nod for Vascepa cardiovascular expansion
- Shionogi scores FDA approval for new cUTI antibiotic
- Merck acquires pre-clinical biotech Calporta for up to $576m
PMHub
Cuttsy + Cuttsy
How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...
Latest intelligence
- What do Healthcare Professionals think about the inclusion of remote selling techniques?
- Evolving to a digitally focused pharma / healthcare company - an organisational roadmap...
- Strengthening business competition and reducing anti-competitive practices
- How the CMA is tackling high prices for essential drugs...
- Pharmaceutical innovation in the APAC region
- A first-of-its-kind study paints a vivid picture of the APAC region’s future...
Quick links
Infographics
